ArticleFrontiers in oncology2021
Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- The Role of [Tomography (Ann Arbor, Mich.) · 2024Pooled it
- The prognostic utility ofFrontiers in immunology · 2024Pooled it
- Trial
- Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy.International journal of hematology · 2026Article
- Predictive values of baselineBone marrow transplantation · 2026Article
- Automated RECOMIA AI-based total metabolic tumor volume in lymphoma - a retrospective study.EJNMMI research · 2026Article
- Imaging the efficacy and side effects of CAR T-cell therapy in children and young adults.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Review
- Clinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumors.Frontiers in immunology · 2026Article
- Added prognostic value of baseline pre-infusionScientific reports · 2025Article
- Predictive Power of Baseline [Diagnostics (Basel, Switzerland) · 2025Article
- Prognostic value of early post-treatmentCancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- The predictive power of baseline metabolic and volumetric [European journal of radiology open · 2025Article
- Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome.PLoS computational biology · 2025Article
- Article
- Baseline Tumor Burden Assessed With AI-Guided PET/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR-T in Aggressive B-Cell Lymphoma.Hematological oncology · 2025Article
- Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma.HemaSphere · 2024Review
- FDG-PET in Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy Toxicity: A Systematic Review.Cancers · 2024Review
- Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.European journal of nuclear medicine and molecular imaging · 2024Article
- Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma.Blood cancer journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has exhibited promising clinical outcomes in treating relapsed/refractory (R/R) B-cell hematologic malignancies. Current studies have shown a close correlation between baseline tumor burden and therapeutic response in CAR-T cell therapy. However, the roles of PET/CT metabolic parameters, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG), remain unclear in this setting. In this study, we retrospectively reviewed 41 R/R NHL patients. 18F-FDG PET/CT was used to measure the average standardized uptake value (SUV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.